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1. Introduction
The conditioned avoidance response model (CAR) is a classic be-
havioral screening tool for chemical compounds with antipsychotic 
activity, as avoidance suppression is a common and distinct prop-
erty of antipsychotic drugs but not that of other psychotropic 
drugs. This task is also useful for the study of the behavioral mech-
anisms of antipsychotic action (Li et al., 2007, 2009a, 2009b, 2004, 
2010, 2012; Mead and Li, 2010; Swalve and Li, 2012). In this regard, 
we have shown that antipsychotic drugs suppress avoidance re-
sponse by attenuating the motivational salience of a conditioned 
stimulus (CS) to elicit avoidance response. The attenuation action 
on the motivational salience of the CS refers to the weakening ef-
fect of antipsychotic treatment on the ability of the CS to instigate 
an active motor response from an organism. We demonstrated 
that the avoidance–disruptive effect of haloperidol, olanzapine and 
clozapine can be potentiated by the increase in number of CS tri-
als in the test sessions (Feng et al., 2012; Li et al., 2007). Further-
more, both clozapine and olanzapine show a greater suppression 
of the avoidance response to a less salient CS than to a more sa-
lient CS (Li et al., 2009b, 2012; Zhang et al., 2011). We also iden-
tified another behavioral mechanism which relates to the drug-
induced alteration of drug sensitivity. We showed that repeated 
treatment with haloperidol, olanzapine or risperidone daily for 5–7 
days tends to cause a progressively increased inhibition of avoid-
ance responding (a sensitization effect), while repeated administra-
tion of clozapine causes a decreased inhibition upon repeated ad-
ministration (a tolerance effect) (Feng et al., 2013b; Li et al., 2010, 
2012; Qiao et al., 2013). These findings are consistent with earlier 
studies showing that the anti-avoidance effect of haloperidol is 
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Abstract
The present study characterized the behavioral mechanisms of avoidance–disruptive effect of quetiapine in the conditioned avoid-
ance response test under two behavioral testing (2 warning signals vs. 1 warning signal) and two drug administration conditions 
(subcutaneous vs. intravenous). In Experiments 1 and 2, well-trained adult male Sprague-Dawley rats were tested under the subcu-
taneous (s.c.) quetiapine treatment (5.0, 15.0, 25.0, 50.0 mg/kg) for 7 days in a novel procedure consisting of two conditioned stim-
uli (CS) (white noise serving as CS1 and pure tone as CS2). Only the highest dose (50.0 mg/kg) produced a persistent suppression 
of the avoidance response without impairing the escape response. The magnitude of suppression of the CS1 avoidance was similar 
to that of CS2 avoidance. No significant group difference was found in the quetiapine (15.0 mg/kg, s.c.) challenge test, indicating a 
lack of a long-term quetiapine effect. In Experiment 3, well-trained rats were tested under the intravenous (i.v.) quetiapine treatment 
(3.0, 9.0, 15.0 mg/kg) for 5 days and challenged with quetiapine (6.0 mg/kg, i.v. followed by 9.0 mg/kg, s.c.). Only the white noise was 
used as the CS. Similar to what was being observed in Experiments 1 and 2, intravenously administered quetiapine dose-depend-
ently suppressed avoidance responding during the drug test days, but did not alter drug sensitivity in the challenge days. Thus, que-
tiapine does not appear to show a preferential inhibition of the avoidance response to a less salient stimulus; and prior quetiapine 
treatment (s.c. and i.v.) does not cause a sensitization or tolerance to quetiapine.
Keywords: Quetiapine, CS1 and CS2, Conditioned avoidance response, Sensitization, Tolerance
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progressively enhanced with each subsequent drug administra-
tion (Fregnan and Chieli, 1980), while that of clozapine is progres-
sively decreased (Sanger, 1985).
The present study was designed to examine the behavioral 
mechanisms of action of quetiapine in the CAR model. Specifically, 
we attempted to determine whether quetiapine disrupts avoidance 
response by attenuating the motivational salience of the CS and 
induces a long-term change in drug sensitivity (either sensitization 
or tolerance). Quetiapine is a widely used atypical antipsychotic 
drug that is effective in the treatment of schizophrenia, bipolar 
disorders and other mental disorders (Zhornitsky et al., 2011). It is 
also used as an adjuvant treatment for major depressive disorder 
and those who did not have an adequate response to antidepres-
sant therapy (Bandelow et al., 2014; Sanford, 2011). Although its 
avoidance disruptive effect has been demonstrated before (Bjork-
holm et al., 2013; Wadenberg et al., 2001), how quetiapine disrupts 
avoidance response and what kind of behavioral pattern (sensiti-
zation or tolerance) it would induce has never been studied. Since 
quetiapine exhibits clozapine-like lower levels of dopamine D2 re-
ceptor occupancy (less than 70%) at therapeutically effective doses 
and a clozapine-like fast dissociation from the D2 receptor (Kapur 
and Seeman, 2000; Kapur et al., 2000), we hypothesized that re-
peated treatment of quetiapine would cause a clozapine-like tol-
erance effect (as opposed to olanzapine-like sensitization) in the 
CAR model. To examine its potential action on the motivational sa-
lience of the CS, we tested quetiapine in a modified CAR paradigm 
involving two types of CS signals with different levels of motiva-
tional salience (Li et al., 2009b, 2012, Zhang et al., 2011).
2. Materials and methods
2.1. Animals
In Experiment 1, 50 adult male drug-naive Sprague-Dawley rats 
(226–250 g upon arrival, Charles River, Portage, MI) were used 
as subjects. In Experiment 2, 40 adult Sprague-Dawley rats (226–
250 g upon arrival) that had been previously used in another study 
were used. These rats had been repeatedly injected with saline, 
nicotine 0.2 mg/kg, or nicotine 0.4 mg/kg, in combination with 
saline or phencyclidine (2.0 mg/kg) for 7 days, and tested for the 
ultrasonic vocalization under PCP and/or nicotine. However, none 
of them had any experience with quetiapine. We used them in this 
study in an attempt to replicate findings from Experiment 1. Be-
cause they had different drug experience compared to rats used 
in Experiment 1, the consistent findings from both experiments 
would enhance the confidence of our findings. In Experiment 3, 
46 adult male drug-naive Sprague-Dawley rats (226–250 g upon 
arrival) were used. Rats were housed two per cage, in transparent 
polycarbonate cages (48.3 × 26.7 × 20.3 cm) under 12-hr light/
dark conditions (light on between 6:30 a.m. and 6:30 p.m.). Room 
temperature was maintained at 22±1 °C with a relative humidity 
of 45–60%. Food and water was available ad libitum. Animals were 
allowed at least 5 days of habituation to the animal facility before 
being used in experiments. All experiments were performed dur-
ing the light cycle and all procedures were approved by the In-
stitutional Animal Care and Use Committee at the University of 
Nebraska–Lincoln.
2.2. Drugs
Quetiapine fumarate (QUE, a gift from the National Institute of 
Mental Health drug supply program) was dissolved in a minimal 
amount (up to 1.5%) of glacial acetic acid and made up to volume 
with distilled sterile water (Kapur et al., 2003 and Wadenberg et al., 
2001), and injected subcutaneously (s.c., 1.0 ml/kg) in Experiments 
1 and 2. For Experiment 3, QUE was dissolved in a minimal amount 
of acetic acid (up to 1%) and diluted to the appropriate concen-
tration with saline (0.9% NaCl solution), the pH was raised slightly 
by adding of a few drops of 1 N NaOH and injected intravenously 
(i.v., 1.0 ml/kg) into a lateral tail vein (Bjorkholm et al., 2013). We 
tested a wide range of QUE doses (3–50 mg/kg) to assess the pos-
sible dose-dependent nature of QUE effects. QUE is shown to sup-
press avoidance response at >20 mg/kg s.c. and >6.0 mg/kg i.v. 
(Bjorkholm et al., 2013 and Wadenberg et al., 2001).
2.3. Two-way avoidance conditioning apparatus
Eight identical two-way shuttle boxes custom designed and man-
ufactured by Med Associates (St. Albans, VT) were used. Each 
box was housed in a ventilated, sound-insulated isolation cubicle 
(96.52 cm W × 35.56 cm D × 63.5 cm H). Each box was 64 cm long, 
30 cm high (from grid floor), and 24 cm wide, and was divided 
into two equal-sized compartments by a partition with an arch 
style doorway (15 cm high × 9 cm wide at base). A barrier (4 cm 
high) was placed between the two compartments, so the rats had 
to jump from one compartment to the other. The grid floor con-
sisted of 40 stainless-steel rods with a diameter of 0.48 cm, spaced 
1.6 cm apart center to center, through which a scrambled foot-
shock (unconditioned stimulus, US, 0.8 mA,) was delivered by a 
constant current shock generator (Model ENV-410B) and scram-
bler (Model ENV-412). The rat location and crossings between 
compartments were monitored by a set of 16 photobeams (ENV-
256-8P) affixed at the bottom of the box (3.5 cm above the grid 
floor). Illumination was provided by two houselights mounted at 
the top of each compartment. The auditory stimuli were generated 
by a programmable audio generator (ANL-926) and delivered by 
the speaker (ENV-224AM). In Experiments 1 and 2, a 76 dB white 
noise (the sound frequency ranged from 10 to 35,000 Hz in 1 Hz 
increment, serving as CS1) and an 85 dB 2800 Hz pure tone (serv-
ing as CS2) were used. In Experiment 3, only the white noise was 
used. Both sounds were produced by a speaker (ENV 224 AMX) 
mounted on the ceiling of the cubicle, centered above the shuttle 
box. Background noise (approximately 74 dB) was provided by a 
ventilation fan affixed at the top corner of each isolation cubicle. 
All training and testing procedures were controlled by Med Asso-
ciates programs running on a computer.
2.4. Experiment 1: Effect of repeated QUE treatments on CS1 and 
CS2 avoidance in normal rats
Fifty rats were first handled and habituated to the CAR boxes for 2 
days (20 min/day), and then trained to make avoidance responses 
to the white noise (CS1) for a total of 10 days/sessions over a 
2-week period. Each session consisted of 30 trials, with inter-trial 
intervals randomly varying between 30 and 60 s. Every trial started 
with the presentation of white noise for 10 s, followed by a con-
tinuous scrambled foot shock (0.8 mA, US, maximum duration = 
5 s) on the grid floor. An avoidance response was registered if a 
rat crossed from one compartment into the other within the 10 s 
of CS1 presentation. An escape was registered if the rat remained 
in the same compartment for more than 10 s and made a crossing 
only after receiving the footshock. If the rat did not switch com-
partments during the entire 5 s presentation of the shock, the trial 
was terminated and the inter-trial interval started.
At the end of the training session, 42 rats reached the train-
ing criterion (>70% CS1 avoidance in each of the last 2 sessions). 
They were first matched on avoidance performance on the last 
training day (pre-drug) to create blocks of rats that were ap-
proximately equal in performance. Within each block, they were 
then randomly assigned to 1 of 5 groups: QUE 5.0 mg/kg (n=8), 
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QUE 15.0 mg/kg (n=8), QUE 25.0 mg/kg (n=10), QUE 50.0 mg/
kg (n=8), and vehicle (n=8), and tested daily in a modified avoid-
ance response test procedure for 7 consecutive days. On each 
test day, rats were first injected with QUE or vehicle (sterile wa-
ter), and tested 1 h later. Each test session consisted of 30 trials 
with 20 CS1 trials intermixed with 10 CS2 (pure tone) trials. The 
CS1 trials were identical to the trials used in the training phase. 
The 10 CS2 trials used a pure tone (10 s, 2800 Hz, 85 dB) as the 
signal with its termination immediately followed by the shock if 
the rats did not make an avoidance response ( Li et al., 2009b, Li 
et al., 2012 and Zhang et al., 2011). This modified avoidance test 
procedure provides a condition to delineate the strength of the 
avoidance disruptive effect of QUE.
One day after the last CAR drug test, all rats were retrained 
drug-free under the CS-only condition (20 CS1 trails and 10 CS2 
trials) for one session, and under the CS–US condition (20 CS1 
trails and 10 CS2 trials) for another session to bring their avoid-
ance back to the pre-drug level. A final challenge test was con-
ducted 24 h later during which all rats were injected with QUE 
15.0 mg/kg, and 1 h later, tested for avoidance performance un-
der the CS-only condition (20 CS1 trails and 10 CS2 trials), as pre-
viously employed (Li et al., 2012). Table 1 summarizes the exper-
imental procedure.
2.5. Experiment 2: effect of repeated QUE treatments on CS1 and 
CS2 avoidance in nicotine and PCP pretreated rats
In this experiment, we replicated Experiment 1 by testing QUE in 
40 rats that were previously treated with nicotine and PCP. The 
PCP-pretreated rats were used here as “diseased” rats, as PCP is 
commonly used to induce changes resembling schizophrenia at 
multiple levels, such as abnormality of glutamatergic neurotrans-
mission and neurodevelopment (Mouri et al., 2007), neuropsy-
chological deficits (Javitt and Zukin, 1991), and prepulse inhibi-
tion deficit (Geyer et al., 2001). Our previous study showed that 
this PCP treatment regimen does cause a disruption of PPI (Li et 
al., 2011), thus, this experiment extended the study of QUE’s an-
tipsychotic effects in normal rats to rats with schizophrenia-like 
symptoms. Rats were first trained to acquire CS1 avoidance re-
sponding for 10 sessions. At the end of the training phase, 34 rats 
had reached the training criterion (>70% avoidance in each of the 
last 2 sessions). They were then semi-randomly assigned to 1 of 5 
groups (matched by their avoidance performance and their pre-
vious experience with nicotine and PCP): QUE 5.0 mg/kg (n = 6), 
QUE 15.0 mg/kg (n = 7), QUE 25.0 mg/kg (n = 6), QUE 50.0 mg/
kg (n = 8), and vehicle (n = 7). The remainder of the experimental 
procedure was identical to that of Experiment 1.
2.6. Experiment 3: effect of repeated QUE treatments (i.v.) on con-
ditioned avoidance in normal rats
To circumvent the first-pass metabolism (Pond and Tozer, 1984) 
and skin lesions produced by s.c. injection, we used the intrave-
nous route of administration in this experiment. This change in in-
jection route would provide a more complete picture of the be-
havioral effects of QUE. In this experiment, 46 rats were trained 
in the same procedure as those in the previous experiments. At 
the end of the training session, 36 rats acquired a robust avoid-
ance responding (≥70% avoidance in each of the last 2 sessions). 
They were matched on the level of avoidance and then randomly 
assigned into 4 groups (n = 8–10/group): vehicle (n = 9), QUE 
3.0 mg/kg (n = 9), QUE 9.0 mg/kg (n = 8), QUE 15.0 mg/kg (n = 
10). They were then tested daily under the CS (white noise)-only 
condition (no shock, 30 trials/session) for 5 consecutive days. This 
procedure has been routinely used in our studies of antipsychotic 
sensitization and tolerance ( Feng et al., 2013a, Feng et al., 2013b, 
Gao and Li, 2013, Gao et al., 2015, Swalve and Li, 2012 and Zhang 
and Li, 2012). On each test day, rats were first injected with vehi-
cle (VEH) or QUE in a lateral tail vein (i.v.) and tested in the CAR 
boxes 20 min later. One day after the last (5th) drug test day, all 
rats were retrained drug-free for 1 session under the CS-only (no 
shock) condition, followed by another under the CS–US condition 
to bring their avoidance responses back to the pre-drug level. On 
the challenge day, all rats were injected with QUE at 6. 0 mg/kg 
(i.v.) and tested for avoidance performance in the CS-only con-
dition (30 trials) 20 min later. One day after this challenge test, 
all rats were once again retrained for 2 sessions (1 under the CS-
only and 1 under the CS–US condition), followed by another QUE 
(9.0 mg/kg, s.c.) challenge test 1 day later (see Table 1).
2.7. Statistical analysis
Avoidance and escape performance was expressed as the mean 
percent+S.E.M. (i.e. number of avoidance or escape response/total 
number of trials). Avoidance data from the repeated drug test days 
and the challenge test were analyzed using a split-plot analysis of 
variance (ANOVA) with the between-subjects factor of drug group, 
and the within-subjects factor of test day and CS condition (CS1 or 
CS2) (only for Experiments 1 and 2). Escape data was similarly an-
alyzed with the exception of no CS condition as a within-subject 
Table 1. A schematic depiction of the experimental procedures used in Experiments 1, 2 and 3. QUE: quetiapine; CS: conditioned stimulus; US: un-
conditioned stimulus.
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factor. One-way ANOVAs followed by post-hoc LSD tests were 
used to compare group differences on specific drug test days and 
challenge days. For all comparisons, significant difference was as-
sumed at P<0.05, and all data was analyzed using SPSS version 21.
3. Results
3.1. Experiment 1: Effect of repeated subcutaneous administration 
of QUE on CS1 and CS2 avoidance in normal rats
3.1.1. Avoidance response during the drug treatment days
Figure 1(A and B) shows the mean percentage of CS1 avoid-
ance (A) and CS2 avoidance (B) on the last training (pre-drug) 
day and throughout the 7 drug test days. On the pre-drug day, 
there were no significant group differences [F(4,37) = 0.952, P = 
0.445]. Throughout the QUE test phase, rats made a higher per-
centage of CS1 avoidances than CS2 avoidances. Only QUE 50 mg/
kg showed an apparent disruption of avoidance responses. A split-
plot ANOVA indicated a main effect of group [F(4,37) = 3.645, P = 
0.013], a main effect of CS condition [F(1,37) = 262.331, P<0.001], 
but no main effect of day [F(6,222) = 1.296, P = 0.260], nor any 
significant interactions (all P>0.284). Post-hoc Fisher’s LSD tests 
showed that the QUE 50 group had significant lower avoidance 
than the vehicle group (P = 0.003). It also had significantly lower 
avoidance than other QUE groups (all P<0.007) except the QUE 25 
group (P = 0.075). One-way ANOVAs followed by post-hoc Fish-
er’s LSD tests on each test day revealed that the QUE 50 group 
had significantly lower CS1 avoidance percentages than the VEH 
group on day 2, P = 0.002, day 5, P = 0.002, day 6, P = 0.011, and 
day 7, P = 0.008; and significantly lower CS2 avoidance percentage 
than the VEH group on day 2, P = 0.017 ( Figure 1B). These find-
ings demonstrated that only the high-dose of QUE (50.0 mg/kg) 
was able to cause a persistent suppression of avoidance responses 
to CS1 (less to CS2) across the drug test sessions.
3.1.2. Escape response during the drug treatment days
Figure 1C shows the mean percentage of total escape responses 
on the last training (pre-drug) day and throughout the 7 drug 
test days. On the pre-drug day, there were no significant group 
differences [F(4,37) = 1.129, P = 0.358]. A split-plot ANOVA indi-
cated that throughout the QUE test phase, there was no main ef-
fect of day [F(6,222) = 1.252, P = 0.281], group [F(4,37) = 1.950, P 
= 0.123], nor a significant interaction between the two [F(24,222) 
= 0.853, P = 0.666].
3.1.3. Avoidance response on the challenge test
Figure 1(D and E) shows the mean percentage of CS1 and CS2 
avoidance responses on the last retraining (drug-free) day and the 
QUE challenge day. On the retraining day, rats in different groups 
all had a higher level of avoidance responding to the CS1 than to 
Figure 1. Effect of repeated subcutaneous administration of quetiapine (5, 15, 25 and 50 mg/kg, sc, −60 min) on CS1 – (A) and CS2 (B) – elicited 
avoidance response and escape response (C) during the 7 drug test days, and its effect on the CS1 – (D) and CS2 – (E) avoidance response on the 
quetiapine challenge day (quetiapine 15 mg/kg, s.c.) in normal rats. Percentages of avoidance or escape response (mean+S.E.M.) made by normal 
rats in the 5 groups on the last training day (pre-drug) and during the 7 drug test days, on the last retraining (drug-free) day and the quetiapine chal-
lenge day are shown. *P<0.05 in comparison to the vehicle group.
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the CS2, and there was no significant group difference. A split-plot 
ANOVA showed a main effect of CS condition [F(1,37) = 68.300, 
P<0.001], but no main effect of group [F(4,37) = 1.387, P = 0.257], 
nor a CS condition × group interaction [F(4,37) = 1.421, P = 0.246]. 
On the challenge day, rats previously treated with various doses of 
QUE for 7 days did not differ from those previously treated with 
vehicle in both CS1 and CS2 avoidance. Two-way ANOVA showed 
a main effect of CS condition [F(1,37) = 135.491, P<0.001], but no 
main effect of group [F(4,37) = 0.866, P = 0.494], nor CS condition 
× group interaction [F(4,37) = 1.086, P = 0.378].
3.2. Experiment 2: Effect of repeated subcutaneous administration 
of QUE on CS1 and CS2 avoidance in nicotine and PCP pretreated 
rats
3.2.1. Avoidance response during the drug treatment days
Figure 2(A and B) shows the mean percentage of CS1 avoidance 
(A) and CS2 avoidance (B) on the last training (pre-drug) day and 
during the 7 drug test days. There was no significant group differ-
ence on the pre-drug day [F(4,37) = 0.446, P = 0.774]. Throughout 
the QUE test phase, only the QUE 50 group displayed significantly 
lower percentages of CS1 and CS2 avoidance, especially towards 
the end of the drug test phase. A split-plot ANOVA indicated a 
main effect of group [F(4,29) = 4.520, P = 0.006], a main effect of 
CS condition [F(1,29) = 180.803, P<0.001], and a significant day 
× group interaction [F(24,174) = 1.812, P = 0.016]. There was no 
main effect of day [F(6,174) = 1.460, P = 0.195], nor any other in-
teractions (all ps>0.217). Post-hoc Fisher’s LSD tests showed the 
QUE 50 group was significantly different from all other groups (all 
p<0.023). One-way ANOVAs followed by post-hoc Fisher’s LSD 
tests on each test day revealed that the QUE 50 group had signif-
icantly lower CS1 avoidance than the VEH group and other QUE 
groups on the last 3 test days, all P<0.016, and significantly lower 
CS2 avoidance on days 3–5 and day 7, all P<0.05.
3.2.2. Escape response during the drug treatment days
Figure 2C shows the mean percentage of escape response on the 
last training (pre-drug) day and during the 7 drug test days. There 
was no significant group difference on the pre-drug day [F(4,29) 
= 0.257, P = 0.903]. In the QUE test phase, a split-plot ANOVA in-
dicated a main effect of group [F(4,29) = 3.647, P = 0.016], but no 
main effect of day [F(6,174) = 1.226, P = 0.295], nor a day × group 
interaction [F(24,174) = 1.216, P = 0.234]. Post-hoc Fisher’s LSD 
tests showed that the QUE 50 group had significantly higher es-
cape percentages than the vehicle group (P = 0.015). It also had 
significantly higher escape percentages than the other QUE groups 
(all P<0.021) except the QUE 15 group (P = 0.153). One-way ANO-
VAs followed by post-hoc Fisher’s LSD tests on each test day re-
vealed that the QUE 50 group had significantly more escapes than 
the VEH group on the last 3 test days, all P<0.013, higher than the 
Figure 2. Effect of repeated subcutaneous administration of quetiapine (5, 15, 25 and 50 mg/kg, sc, −60 min) on CS1 – (A) and CS2 (B) – elicited avoid-
ance response, escape response (C) during the 7 drug test days, and its effect on the CS1 – (D) and CS2 – (E) avoidance response on the quetiapine 
challenge day (quetiapine 15 mg/kg, s.c.) in nicotine and phencyclidine pretreated rats. Percentages of avoidance or escape response (mean+S.E.M.) 
made by nicotine and phencyclidine pretreated rats in the 5 groups on the last training day and during the 7 drug test days, on the last retraining 
(drug-free) day and the quetiapine challenge day are shown. *P<0.05 in comparison to the vehicle group.
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QUE 25 group on all days except day 1 and day 4, all P<0.008, and 
higher than the QUE 5 group on days 2–3 and day 5, all P<0.026.
3.2.3. Avoidance response on the challenge test
Figure 2(D and E) shows the mean percentage of CS1 and CS2 
avoidance responses on the last retraining (drug-free) day and the 
QUE challenge day. Before the QUE challenge, rats showed signif-
icantly higher CS1 avoidance relative to CS2 avoidance, but there 
was no significant group difference. There was a main effect of CS 
condition [F(1,29) = 55.272, P<0.001], but no main effect of group 
[F(4,29) = 1.100, P = 0.375], nor significant CS condition × group 
interaction [F(4,29) = 1.652, P = 0.188]. On the challenge test, the 
group differences were not apparent. A split-plot ANOVA showed 
a main effect of CS condition [F(1,29) = 56.247, P<0.001], but no 
main effect of group [F(4,29) = 1.241, P = 0.316], nor a signifi-
cant CS condition × group interaction [F(4,29) = 1.023, P = 0.412].
3.3. Experiment 3: Effect of repeated intravenous administration of 
QUE treatments on conditioned avoidance in normal rats
3.3.1. Avoidance response during the drug treatment days
Figure 3A shows the mean percentage of avoidance responses 
on the last training (pre-drug) day and throughout the 5 drug 
test days. On the pre-drug day, there was no significant group 
difference [F(3,32) = 0.589, P = 0.627]. Throughout the QUE test 
phase, QUE 9.0 and 15.0 mg/kg (i.v.) caused a strong suppression 
of avoidance responding. A split-plot ANOVA revealed a main ef-
fect of group [F(3,32) = 30.367, P<0.001], but no main effect of 
day [F(4,128) = 1.687, P = 0.157], nor any significant interaction 
between the two [F(12,128) = 1.408, P = 0.170]. Post-hoc LSD 
tests showed that all 3 QUE groups had significantly lower avoid-
ance than the VEH group (QUE 3.0, P = 0.013; QUE 9.0 and 15.0, 
both P<0.001). QUE 9.0 and 15.0 groups also had significantly 
lower avoidance than the QUE 3.0 group (both P<0.001). One-
way ANOVA on each test day revealed that the QUE 9.0 and 15.0 
groups had significantly lower avoidance than the VEH group on 
all 5 days (all P<0.004), while the QUE 3.0 group showed lower 
avoidance than the VEH group only on days 4 and 5 (P<0.001). 
Additionally, QUE 9.0 and 15.0 groups have lower avoidance than 
the QUE 3.0 groups on all 5 days (all P<0.045). These findings 
indicate that QUE was able to dose-dependently cause a per-
sistent suppression of the avoidance response across the drug 
test sessions.
3.3.2. Avoidance response on the challenge test
Figure 3B shows the mean percentage of avoidance responses on 
the 1st retraining day and the 1st QUE challenge day (6.0 mg/kg, 
i.v.). No significant group difference was found [the 1st pre-drug 
day, F(3,32) = 1.716, P = 0.183; the 1st challenge day, F(3,32) = 
0.477, P = 0.700].
After 2 days of retraining, all rats were challenged again with 
QUE (9.0 mg/kg, s.c.). As shown in Figure 3C, none of the groups 
differed from each other on the 2nd retraining day [F(3,32) = 
0.880, P = 0.462] or on the 2nd challenge day [F(3,32) = 0.434, P 
= 0.730], indicating no long-term alteration of behavioral sensitiv-
ity to QUE after repeated intravenous QUE treatment.
4. Discussion
Using heterogeneous groups of rats (i.e. drug-naive and nicotine 
and/or PCP treated rats), two CAR test procedures (CS1+CS2 vs. 
CS1-only) and two drug administration routes (s.c. vs. i.v.), we dem-
onstrated that under the subcutaneous administration condition, 
only the high-dose of QUE (50 mg/kg) was able to cause a persis-
tent and comparable suppression of avoidance responses to both 
CS1 and CS2 during the repeated drug treatment phase (Experi-
ments 1 and 2; Figure 1 and Figure 2). However, under the intra-
venous administration condition, all 3 doses of QUE (3.0, 9.0 and 
15.0 mg/kg) exhibited this effect (Experiment 3; Figure 3). In the 
challenge tests when all rats were injected with QUE, those who 
had been treated with QUE previously did not make more or fewer 
avoidance responses than those who had been treated with vehi-
cle. This result was consistent across the 3 experiments, suggest-
ing that prior QUE experience or treatment history did not cause a 
long-term change in the behavioral sensitivity to QUE, regardless of 
the route of drug administration. Thus, under the current test con-
ditions, QUE does not appear to show a clozapine-like tolerance ef-
fect ( Feng et al., 2013b, Li et al., 2012, Li et al., 2010 and Qiao et al., 
2013), nor does it show an olanzapine-like sensitization effect ( Li 
et al., 2009b, Li et al., 2010 and Swalve and Li, 2012), although they 
all belong to the same atypical antipsychotic drug group.
As mentioned in Section 1, QUE’s avoidance disruptive effect 
has been demonstrated before (Bjorkholm et al., 2013 and Waden-
berg et al., 2001). Wadenberg et al. (2001) examined the relation 
between striatal dopamine D2 occupancy and efficacy of avoidance 
suppression. They found that QUE at 5, 10, 25, 50, 75 and 100 mg/
kg gave rise to a dose-dependent increase in striatal dopamine 
Figure 3. Effect of repeated intravenous administration of quetiapine (3, 9 and 15 mg/kg, i.v., −20 min) on conditioned avoidance response during the 
5 drug test days (A) and the 2 drug challenge days (B: quetiapine 6 mg/kg, i.v.; C: quetiapine 9 mg/kg, s.c.). Percentages of avoidance (mean+S.E.M.) 
made by normal rats in the 4 groups on the last training day (pre-drug) and during the 5 drug test days, on the last retraining (drug-free) day and 
the quetiapine challenge day are shown. **P<0.01, ***P<0.001 in comparison to the vehicle group.
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D2 occupancy in rats (58–81%) at the 1 h time point after injec-
tion. In the avoidance test, they found that QUE at 20 or 40 mg/kg 
suppressed avoidance responding 20 min after injection. QUE at 
40 mg/kg maintained its suppression even 90 min after adminis-
tration. Bjorkholm et al. (2013) used an intravenous drug adminis-
tration route and found that QUE at 6 and 9 mg/kg (i.v.) produced 
a relatively transient suppression of avoidance 5 min after injec-
tion, but not after 30 min. In the present study, we also showed 
that QUE at 9.0 and 15.0 mg/kg administered intravenously dis-
rupted avoidance responding at 20 min post injection and this ef-
fect persisted throughout the 5-day testing period (Experiment 3). 
One methodological difference between Bjorkholm et al. (2013) 
and Experiment 3 was that we tested rats under the CS-only con-
dition, while Bjorkholm et al. (2013) tested them under the CS–US 
(shock) condition. This difference might explain why we observed 
such a robust and severe suppression (reduced to ~20% avoidance 
level), while Bjorkholm et al. (2013) only observed a mild suppres-
sion (reduced to ~50% level).
In comparison to other atypical antipsychotic drugs, such as 
olanzapine, risperidone and clozapine, QUE displays a relatively 
weak and short duration of action on avoidance responding. One 
obvious reason is that QUE has a faster dissociation rate from do-
pamine D2 receptors and does not cause a sustained higher D2 
occupancy (>80%) than other atypical drugs (Kapur and Seeman, 
2000). The QUE 50 mg/kg (s.c.) tested in the present study only 
produces 74% D2 occupancy (Wadenberg et al., 2001). Given that 
D2 blockade is critical for antipsychotic action (Seeman, 2002) and 
action in the CAR model (Wadenberg et al., 2001), it could be said 
that QUE transiently disrupts avoidance behavior because it only 
transiently blocks dopamine D2 receptors. The second possible 
reason is that QUE does not produce norquetiapine in rodents 
(Bjorkholm et al., 2013). Because norquetiapine has a potent inhib-
itory action against the norepinephrine transporter (NET) (Jensen 
et al., 2008), and the NET inhibition by reboxetine (a selective NET 
inhibitor) often enhances the avoidance–disruptive effect of QUE 
(Bjorkholm et al., 2013), it is reasonable to suggest that norque-
tiapine could potentially enhance the avoidance–disruptive effect 
of QUE. Therefore, lack of this metabolite in rats may contribute 
to the overall weak effect of QUE.
In our previous studies of the motivational salience attenua-
tion action of antipsychotics, we have shown that atypical anti-
psychotics (e.g. clozapine, olanzapine and risperidone) suppress 
avoidance responses elicited by a less salient conditioned stimulus 
(e.g. pure tone CS2 as it was only partially reinforced) to a greater 
extent than avoidances elicited by a more salient stimulus (e.g. 
white noise CS1 as it was reinforced in every trial), regardless of 
the baseline difference in the number of CS1 and CS2 avoidances 
( Li et al., 2009b, 2012; Zhang et al., 2011). The differential sensitiv-
ity to QUE (50 mg/kg) of CS1 and CS2 avoidance was not apparent 
in our current experimental condition, although we did observe 
that prior conditioning to CS1 renders CS2 less effective in elicit-
ing an avoidance response (Figure 1 and Figure 2). Why QUE did 
not show a preferential suppression of CS2 avoidance over CS1 
avoidance is not entirely clear. Besides QUE’s relative weaker ef-
fect on avoidance than other atypicals, the procedural differences 
between the present study and previous ones could be a factor. In 
the previous studies, rats were trained in the CS1 and CS2 avoid-
ance conditioning procedure first, and then tested in the same 
procedure; while in the present study, rats were first trained in the 
CS1 avoidance and then tested in the mixed CS1 and CS2 avoid-
ance procedure. This issue will be further examined in the future 
study to directly compare QUE with other atypical antipsychotics 
in the same test procedure.
As mentioned before, our recent work on the long-term ef-
fects of repeated antipsychotic treatment has revealed two basic 
behavioral patterns: sensitization and tolerance in the CAR model 
and also in the phencyclidine-induced hyperlocomotion model 
( Feng et al., 2013b, Gao and Li, 2013, Li et al., 2012, Mead and 
Li, 2010, Qiao et al., 2013, Swalve and Li, 2012 and Zhang and Li, 
2012). Specifically, we show that repeated administration of hal-
operidol, olanzapine or risperidone daily for 5–7 days tends to 
cause a progressively increased inhibition of avoidance respond-
ing. When rats are given a challenge dose of these drugs at a later 
point, they often make significantly fewer avoidance responses 
than those that are treated with these drugs for the first time 
( Li et al., 2009b, Li et al., 2010, Mead and Li, 2010, Qiao et al., 
2013, Swalve and Li, 2012 and Zhang and Li, 2012). Clozapine, 
on the other hand, displays an opposite behavioral pattern (tol-
erance). During the daily drug test phase, repeated administra-
tion of clozapine causes no apparent sensitization or tolerance. 
But on the challenge test, rats previously treated with clozapine 
make significantly more avoidance responses than those that are 
treated with clozapine for the first time (Feng et al., 2013b, Li et 
al., 2010 and Qiao et al., 2013). QUE, very much like clozapine, has 
high to moderate affinities for α1-adrenergic, 5-HT2A, H1 and low 
affinities for D1, D2 and α2-adrenergic receptors (Jibson and Tan-
don, 1998; Miyamoto et al., 2005), and fast dissociation from the 
D2 receptor ( Kapur and Seeman, 2000; Kapur et al., 2000). We 
thus hypothesized that repeated treatment of QUE would cause a 
clozapine-like tolerance effect in the CAR model. Results indicate 
that although there was a trend for QUE tolerance, i.e. rats pre-
viously treated with QUE had higher avoidance than those previ-
ously treated with vehicle, the difference failed to reach a signifi-
cant level based on the one-way ANOVA. Therefore, if QUE does 
cause a clozapine-like tolerance effect, this effect may still be rel-
atively weak. Because antipsychotic sensitization and tolerance are 
modulated by various experimental parameters (e.g. drug doses, 
number of drug administrations, test–retest intervals, etc.), more 
studies are needed to further determine the features of QUE re-
peated treatment effect.
The clinical efficacy of QUE is similar to those of other atypi-
cal antipsychotic drugs. Its mechanism of action is also relatively 
similar. Like other atypical drugs, the antipsychotic efficacy of QUE 
in schizophrenia is thought to be mediated by its transient high 
D2 blockade in the striatum (Kapur et al., 2000) or a combination 
of dopamine D2 and serotonin 5-HT2 antagonisms in the cortical 
and subcortical areas (Ichikawa et al., 2002). Even though both clo-
zapine and QUE are well tolerated by the patients, they have dif-
ferent pharmacokinetics. For example, the elimination half-life of 
QUE (approximately 6 h) is shorter than that of clozapine (more 
than 10.2 h), and its active metabolites, e.g. norclozapine (10.2 h) 
( Fang and Mosier, 2014; Guitton et al., 1999; Winter et al., 2008). 
Therefore, although the present study did not find strong evidence 
at the behavioral level linking QUE with other atypicals, especially 
clozapine, its behavioral similarities with other atypicals should not 
be dismissed. Indeed, in the phencyclidine-induced prepulse inhi-
bition (PPI) of acoustic startle reflex test (Li et al., 2011), we found 
that repeated administration of both QUE and clozapine similarly 
maintained their improvement effect on phencyclidine-induced 
PPI deficits. Future work directly comparing QUE with other atyp-
icals in the CAR model as well as other behavioral tests of anti-
psychotic activity (e.g. phencyclidine-induced hyperlocomotion 
model) may be able to reveal the behavioral mechanisms of ac-
tion of QUE and its possible similarities and differences to other 
drugs. Overall, the present findings suggest that quetiapine is ca-
pable of suppressing avoidance response and maintains its sup-
pression over the treatment period, a profile shared by other atyp-
ical antipsychotic drugs. However, prior quetiapine treatment does 
not cause a long-term change in drug sensitivity (i.e. sensitization 
or tolerance), a peculiar feature deserving further investigation.
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